Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118–32.

Article  CAS  PubMed  Google Scholar 

Greuter T, Rieder F, Kucharzik T, Peyrin-Biroulet L, Schoepfer AM, Rubin DT, et al. Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021;70(4):796–802.

Article  CAS  PubMed  Google Scholar 

Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol. 1996;9(6):456–60.

Article  CAS  PubMed  Google Scholar 

Grimstad T, Norheim KB, Isaksen K, Leitao K, Hetta AK, Carlsen A, et al. Fatigue in newly diagnosed inflammatory bowel disease. J Crohns Colitis. 2015;9(9):725.

Article  PubMed  Google Scholar 

Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12(2):123–37.

Article  CAS  PubMed  Google Scholar 

Dantzer R, Heijnen CJ, Kavelaars A, Laye S, Capuron L. The neuroimmune basis of fatigue. Trends Neurosci. 2014;37(1):39–46.

Article  CAS  PubMed  Google Scholar 

Ilanges A, Shiao R, Shaked J, Luo J-D, Yu X, Friedman JM. Brainstem ADCYAP1+ neurons control multiple aspects of sickness behaviour. Nature. 2022;609(7928):761–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–83.

Article  CAS  PubMed  Google Scholar 

Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol. 2007;34(5):1174–7.

PubMed  Google Scholar 

Hart AL, Lomer M, Verjee A, Kemp K, Faiz O, Daly A, et al. What are the top 10 research questions in the treatment of inflammatory bowel disease? A priority setting partnership with the James Lind Alliance. J Crohns Colitis. 2017;11(2):204–11.

Article  PubMed  Google Scholar 

Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, et al. CORE-IBD: A Multidisciplinary International Consensus Initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease. Gastroenterology. 2022.

Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2009;2:101–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farrell D, Artom M, Czuber-Dochan W, Jelsness-Jørgensen LP, Norton C, Savage E. Interventions for fatigue in inflammatory bowel disease. Cochrane Database Syst Rev. 2020;4(4): CD012005.

PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clin Res Ed). 2021;29(372): n71.

Google Scholar 

Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, et al. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. www.training.cochrane.org/handbook: Cochrane; 2021.

Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Marshall C, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. www.training.cochrane.org/handbook: Cochrane; 2022.

Glanville J, Dooley G, Wisniewski S, Foxlee R, Noel-Storr A. Development of a search filter to identify reports of controlled clinical trials within CINAHL Plus. Health Info Libr J. 2019;36(1):73–90.

Article  PubMed  Google Scholar 

Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. 1993.

Maruish M, Kosinski M, Bjorner J, Gandek B, Turner-Bowker D, Ware J. User’s manual for the SF-36v2® health survey, 3rd ed. QualityMetric Inc; 2011.

Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63–74.

Article  CAS  Google Scholar 

Higgins J, Savović J, Page M, Elbers R, Sterne J. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. Cochrane handbook for systematic reviews of interventions version 63 (Updated february 2022). www.training.cochrane.org/handbook: Cochrane; 2022.

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.

Article  CAS  PubMed  Google Scholar 

Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672–83.

Article  CAS  PubMed  Google Scholar 

Sandborn WJ, Ghosh S, Panes J, Schreiber S, D’Haens G, Tanida S, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139-49.e14.

Article  CAS  PubMed  Google Scholar 

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–60.

Article  CAS  PubMed  Google Scholar 

Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36.

Article  CAS  PubMed  Google Scholar 

Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007;102(4):794–802.

Article  CAS  PubMed  Google Scholar 

Sands BE, Han C, Gasink C, Jacobstein D, Szapary P, Gao LL, et al. The effects of ustekinumab on health-related quality of life in patients with moderate to severe Crohn’s disease. J Crohns Colitis. 2018;12(8):883–95.

Article  PubMed  Google Scholar 

Dudley-Brown S, Nag A, Cullinan C, Ayers M, Hass S, Panjabi S. Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy. Gastroenterol Nurs. 2009;32(5):327–39.

Article  PubMed  Google Scholar 

Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Wiley; 2009.

Book  Google Scholar 

Higgins J, Li T, Deeks J. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021, Section 6.5.2.10. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. Available from https://training.cochrane.org/handbook.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, et al. Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies. J Crohns Colitis. 2018;12(2):145–56.

Article  PubMed  Google Scholar 

Ghosh S, Colombel J-F, Vermeire S, Lee S D, Lee W-J, Zhou W, et al. Improved patient-reported outcomes with upadacitinib as an induction therapy for patients with ulcerative colitis: data from u-achieve. UEG Week 2018. Vienne, Austria; 2018.

Higgins J, Li T, Deeks J. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021, Section 6.5.2.3. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. https://training.cochrane.org/handbook.

Higgins J, Li T, Deeks J. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021, Section 6.5.1.2. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. https://training.cochrane.org/handbook.

Danese S, Vermeire S, D’Haens G, Panés J, Dignass A, Magro F, et al. P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn’s disease: results up to Week 48 of the STARDUST trial. J Crohn’s Colitis. 2021;15(Supplement 1):S330–1.

Article  Google Scholar 

Bradburn M, Deeks J, Altman D. Metan—an alternative meta-analysis command. Stata Tech Bull. 1999;8.

Sullivan GM, Feinn R. Using effect size-or why the P value is not enough. J Grad Med Educ. 2012;4(3):279–82.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed). 2003;327(7414):557–60.

Article  Google Scholar 

Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord RM, Sterne JAC. Metan: fixed- and random-effects meta-analysis. Stand Genom Sci. 2008;8(1):3–28.

Google Scholar 

Blum SI, Tourkodimitris S, Ruth A. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder. J Affect Disord. 2015;1(170):230–6.

Article  Google Scholar 

Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):811–9.

PubMed  Google Scholar 

Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (Clin Res Ed). 2011;22(343): d4002.

Article  Google Scholar 

Skoie IM, Dalen I, Omdal R. Effect of biological treatment on fatigue in psoriasis: a systematic review and meta-analysis. Am J Clin Dermatol. 2019;20(4):493–502.

Article  PubMed  Google Scholar 

Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016;2016(6): CD008334.

PubMed  PubMed Central  Google Scholar 

Omdal R, Gunnarsson R. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis—a pilot study. Rheumatol Int. 2005;25(6):481–4.

Article  CAS  PubMed  Google Scholar 

Cavelti-Weder C, Furrer R, Keller C, Babians-Brunner A, Solinger AM, Gast H, et al. Inhibition of IL-1beta improves fatigue in type 2 diabetes. Diabetes Care. 2011;34(10): e158.

Article  CAS